@article {142, title = {Identification of rare and common regulatory variants in pluripotent cells using population-scale transcriptomics.}, journal = {Nat Genet}, volume = {53}, year = {2021}, month = {2021 03}, pages = {313-321}, abstract = {

Induced pluripotent stem cells (iPSCs) are an established cellular system to study the impact of genetic variants in derived cell types and developmental contexts. However, in their pluripotent state, the disease impact of genetic variants is less well known. Here, we integrate data from 1,367 human iPSC lines to comprehensively map common and rare regulatory variants in human pluripotent cells. Using this population-scale resource, we report hundreds of new colocalization events for human traits specific to iPSCs, and find increased power to identify rare regulatory variants compared with somatic tissues. Finally, we demonstrate how iPSCs enable the identification of causal genes for rare diseases.

}, keywords = {Bardet-Biedl Syndrome, Calcium Channels, Cell Line, Cerebellar Ataxia, DNA Methylation, Gene Expression, Genetic Variation, Humans, Induced Pluripotent Stem Cells, Polymorphism, Single Nucleotide, Proteins, Quantitative Trait Loci, Rare Diseases, Regulatory Sequences, Nucleic Acid, Sequence Analysis, RNA, Whole Genome Sequencing}, issn = {1546-1718}, doi = {10.1038/s41588-021-00800-7}, author = {Bonder, Marc Jan and Smail, Craig and Gloudemans, Michael J and Fr{\'e}sard, Laure and Jakubosky, David and D{\textquoteright}Antonio, Matteo and Li, Xin and Ferraro, Nicole M and Carcamo-Orive, Ivan and Mirauta, Bogdan and Seaton, Daniel D and Cai, Na and Vakili, Dara and Horta, Danilo and Zhao, Chunli and Zastrow, Diane B and Bonner, Devon E and Wheeler, Matthew T and Kilpinen, Helena and Knowles, Joshua W and Smith, Erin N and Frazer, Kelly A and Montgomery, Stephen B and Stegle, Oliver} } @article {85, title = {A brief history of human disease genetics.}, journal = {Nature}, volume = {577}, year = {2020}, month = {2020 01}, pages = {179-189}, abstract = {

A primary goal of human genetics is to identify DNA sequence variants that influence biomedical traits, particularly those related to the onset and progression of human disease. Over the past 25 years, progress in realizing this objective has been transformed by advances in technology, foundational genomic resources and analytical tools, and by access to vast amounts of genotype and phenotype data. Genetic discoveries have substantially improved~our understanding of the mechanisms responsible for many rare and common diseases and driven development of novel preventative and therapeutic strategies. Medical innovation will increasingly focus on delivering care tailored to individual patterns of genetic predisposition.

}, keywords = {Animals, Genetic Testing, Genetic Variation, Genomics, Genotype, Humans, Phenotype, Rare Diseases}, issn = {1476-4687}, doi = {10.1038/s41586-019-1879-7}, author = {Claussnitzer, Melina and Cho, Judy H and Collins, Rory and Cox, Nancy J and Dermitzakis, Emmanouil T and Hurles, Matthew E and Kathiresan, Sekar and Kenny, Eimear E and Lindgren, Cecilia M and MacArthur, Daniel G and North, Kathryn N and Plon, Sharon E and Rehm, Heidi L and Risch, Neil and Rotimi, Charles N and Shendure, Jay and Soranzo, Nicole and McCarthy, Mark I} } @article {63, title = {Identification of rare-disease genes using blood transcriptome sequencing and large control cohorts.}, journal = {Nat Med}, volume = {25}, year = {2019}, month = {2019 06}, pages = {911-919}, abstract = {

It is estimated that 350 million individuals worldwide suffer from rare diseases, which are predominantly caused by mutation in a single gene. The current molecular diagnostic rate is estimated at 50\%, with whole-exome sequencing (WES) among the most successful approaches. For patients in whom WES is uninformative, RNA sequencing (RNA-seq) has shown diagnostic utility in specific tissues and diseases. This includes muscle biopsies from patients with undiagnosed rare muscle disorders, and cultured fibroblasts from patients with mitochondrial disorders. However, for many individuals, biopsies are not performed for clinical care, and tissues are difficult to access. We sought to assess the utility of RNA-seq from blood as a diagnostic tool for rare diseases of different pathophysiologies. We generated whole-blood RNA-seq from 94 individuals with undiagnosed rare diseases spanning 16 diverse disease categories. We developed a robust approach to compare data from these individuals with large sets of RNA-seq data for controls (n = 1,594 unrelated controls and n = 49 family members) and demonstrated the impacts of expression, splicing, gene and variant filtering strategies on disease gene identification. Across our cohort, we observed that RNA-seq yields a 7.5\% diagnostic rate, and an additional 16.7\% with improved candidate gene resolution.

}, keywords = {Acid Ceramidase, Case-Control Studies, Child, Child, Preschool, Cohort Studies, Female, Genetic Variation, Humans, Male, Models, Genetic, Mutation, Oxidoreductases Acting on CH-CH Group Donors, Potassium Channels, Rare Diseases, RNA, RNA Splicing, Sequence Analysis, RNA, Whole Exome Sequencing}, issn = {1546-170X}, doi = {10.1038/s41591-019-0457-8}, author = {Fr{\'e}sard, Laure and Smail, Craig and Ferraro, Nicole M and Teran, Nicole A and Li, Xin and Smith, Kevin S and Bonner, Devon and Kernohan, Kristin D and Marwaha, Shruti and Zappala, Zachary and Balliu, Brunilda and Davis, Joe R and Liu, Boxiang and Prybol, Cameron J and Kohler, Jennefer N and Zastrow, Diane B and Reuter, Chloe M and Fisk, Dianna G and Grove, Megan E and Davidson, Jean M and Hartley, Taila and Joshi, Ruchi and Strober, Benjamin J and Utiramerur, Sowmithri and Lind, Lars and Ingelsson, Erik and Battle, Alexis and Bejerano, Gill and Bernstein, Jonathan A and Ashley, Euan A and Boycott, Kym M and Merker, Jason D and Wheeler, Matthew T and Montgomery, Stephen B} }